CW120N LCD Monitor System is intended to be used in displaying digital medical images for review and analysis by trained medical practitioners. It is specifically designed for digital mammography applications and digital breast tomosynthesis applications.

Device Description

CW120N LCD Monitor is intended to provide high resolution color and grayscale medical imaging for PACS and Radiology system. This Medical Monitor is intended to be used by trained medical practitioners for displaying, reviewing, and analysis of medical images.

EzCal ver.2 is a software solution which enables the user to modify display output to meet DICOM Part 14 GSDF and other key industry standards.

CW120N is being provided with the calibration software EzCal v.2 (developed by Qubyx Inc.) when requested by the customer.

AI/ML Overview

The provided text is related to a 510(k) premarket notification for a medical monitor system (CW120N). This document describes the device, its intended use, and its equivalence to a predicate device. However, it does not contain information about a study proving the device meets acceptance criteria in the context of an AI/algorithm-based diagnostic device.

The "acceptance criteria" discussed in the document are limited to the performance of the display hardware itself, such as luminance, resolution, and color uniformity, and compliance with general medical electrical equipment standards (IEC 60601-1 and IEC 60601-1-2).

Therefore, based on the provided text, I cannot complete the requested table and sections regarding an AI/algorithm study. The document explicitly states: "No clinical studies were considered necessary and performed." This indicates that there was no study involving human readers, ground truth establishment, or sample sizes for diagnostic efficacy of an AI component.

Here's an explanation based on the available information:

Description of the Device and its Purpose:
The CW120N LCD Monitor System is a display device intended for viewing digital medical images, specifically for digital mammography and digital breast tomosynthesis applications. It is a hardware product, not an AI or algorithm-based diagnostic tool that interprets images. Its functionality is to accurately display images.

Acceptance Criteria for CW120N (as a display device):
The acceptance criteria are derived from bench tests to ensure the monitor's display quality and compliance with relevant standards for medical displays. These are physical and performance characteristics of the monitor, not diagnostic accuracy criteria for an AI.

Based on the provided text, the device is a medical display monitor, not an AI/algorithm-based diagnostic device. Therefore, information regarding acceptance criteria and studies for AI performance (such as sensitivity, specificity, MRMC studies, ground truth, and training sets for an algorithm) is not present in the document.

If the request implied a different type of device or study not contained within the provided text, I would not be able to generate that information.

Summary

{0}------------------------------------------------

April 8, 2021

Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health and Human Services logo on the left and the FDA text logo on the right. The FDA text logo is in blue and includes the letters "FDA" in a square, followed by the words "U.S. FOOD & DRUG" on one line and "ADMINISTRATION" on the next line.

Wide Corporation % Mr. Yeojin Yun RA Manager 15F, The First Tower III, 602, Dongtangiheung-Ro Hwaseong-Si, Gyeonggi-Do 18469 REPUBLIC OF KOREA

Re: K210491

Trade/Device Name: CW120N Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: Class II Product Code: PGY Dated: January 27, 2021 Received: February 19, 2021

Dear Mr. Yun:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for

{1}------------------------------------------------

devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Michael D. O'Hara
For

Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K210491

Device Name CW120N

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

[As required by 21 CFR 807.92]

This 510(k) summary of safety and effectiveness information is prepared in accordance with 21 CFR 807.92

1. Date Prepared [21 CFR 807.92(a) (1)]

01/27/2021

2. Submitter's Information [21 CFR 807.92(a) (1)]

Name of Sponsor:	WIDE Corporation.
Address:	15F, The First Tower III, 602, Dongtangiheung-Ro,Hwaseong-Si, Gyeonggi-Do 18469, Republic of Korea
Contact Name:	YeoJin Yun
Telephone #:	+82-31-218-1675
Fax #:	+82-31-376-9600
Email:	yyjin@widecorp.com
Registration Number:	3004082357
Name of Manufacturer:	Same as Sponsor

3. Trade Name, Common Name, Classification [21 CFR 807.92(a) (2)]

Model Name:	CW120N
Common Name:	TFT LCD Medical Monitor System
Classification Name:	Picture archiving and communications system
Regulation Number:	21 CFR 892.2050
Product Code:	PGY
Device Class:	2
Review Panel:	Radiology

4. Identification of Predicate Device(s) [21 CFR 807.92(a) (3)]

510(k) Number: K200485
Applicant: EIZO CORPORATION
Model Name: RadiForce RX1270, RadiForce RX1270-AR
Common Name: 78.4 cm (30.9 inch) class Color LCD Monitor
Classification Name: Picture archiving and communications system
Regulation Number: 21 CFR 892.2050
Product Code: PGY
Device Class: 2

K210491

510(k) Summary 1/4

{4}------------------------------------------------

5. Description of the Device [21 CFR 807.92(a) (4)]

EzCal ver.2 is a software solution which enables the user to modify display output to meet DICOM Part 14 GSDF and other key industry standards.

CW120N is being provided with the calibration software EzCal v.2 (developed by Qubyx Inc.) when requested by the customer.

6. Intended Use [21 CFR 807.92(a) (5)]

CW120N LCD Monitor System is intended to be used in displaying and viewing digital medical images for review and analysis by trained medical practitioners. It is specifically designed for digital mammography applications and digital breast tomosynthesis applications.

7. Technological Characteristics [21 CFR 807.92(a) (6)]

The table below presents comparisons between the subject device (CW120N) and the predicate device (K200485):

Attributes	Predicate Device	Subject Device	DiscussionofDifferences
Product	RadiForce RX1270,RadiForce RX1270-AR	CW120N	-
Screentechnology	TFT ColorLCD Panel (IPS)	TFT ColorLCD Panel (IPS)	-
Screen size	78.4cm / 30.9"	78.4cm / 30.9"	-
Resolution	4200 x 2800(3:2aspect ratio)	4200 x 2800(3:2aspect ratio)	-
Pixel pitch	0.1554 mm x 0.1554mm	0.1554 mm x 0.1554mm	-
Backlight type	LED	LED	-
Maximum luminance	1,200 cd/m²	1,200 cd/m²	-
DICOM calibratedluminance	500 cd/m²	500 cd/m²	-
Contrast ratio(typical)	1500 : 1	1500 : 1	-
ResponseTime(typical)	12ms(black-white-black)	14ms (gray-to-gray)	Provided by the panelmanufacturers.
Digital ScanningFrequency(H / V)	HDMI: 31 - 160 kHz /59 - 61 Hz(VGA Text: 69 - 71 Hz)DisplayPort: 31 - 175kHz / 29 -61 Hz(VGA Text: 69 - 71 Hz)Frame synchronousmode:29.5 - 30.5 Hz, 59 - 61Hz	DisplayPort170.4KHz, 60Hz	Differences bymanufacturers.

510(k) Summary 2/4

{5}------------------------------------------------

Analog ScanningFrequency(H / V)	HDMI: 31 - 160 kHz /59 - 61 Hz(VGA Text: 69 - 71 Hz)DisplayPort: 31 - 175kHz / 29 -61 Hz(VGA Text: 69 - 71 Hz)Frame synchronousmode:29.5 - 30.5 Hz, 59 - 61Hz		Differences bymanufacturers.
Input video signals	DisplayPort x 2,HDMI x 1	DisplayPort x 1	Differences bymanufacturers.
Ambient Light Sensor	Yes	Yes	-
Luminance calibrationtools	Integrated opticalsensorExternal optical sensorCalibration software:RadiCS	IQ Sensor,Calibration software:EzCal	It is only a difference interms of eachmanufacturer, but thefunctions are similar.
Quality-controlprocedures	RadiCS	EzCal	It is only a difference interms of eachmanufacturer, but thefunctions are similar.

CW120N Device is substantially equivalent to the currently marketed and predicate devices in terms of design features, indications for use, and safety and effectiveness.

9. Summary of Non-Clinical Data

CW120N comply with the following international and FDA-recognized consensus standards:

IEC 60601-1:	Medical Electrical Equipment -- Part 1: GeneralRequirements For Basic Safety And Essential Performance
IEC 60601-1-2:	Medical Electrical Equipment - Part 1-2: GeneralRequirements For Basic Safety And Essential Performance -Collateral Standard: Electromagnetic Compatibility -Requirements And Tests

The bench tests below were performed on the CW120N following the instructions in 'Display Devices for Diagnostic Radiology – Guidance for Industry and Food and Drug Administration Staff, issued on October 2, 2017.

· Test Item

Pixel Defects, Artifacts, Luminance, Reflection, Luminance Uniformity, Resolution, Noise, Veiling Glare, Color Uniformity, Luminance Response, Luminance at 30° and 45° in diagonal, horizontal, and vertical directions, Temporal Performance Test, Color Tracking, Gray Tracking, MTF

{6}------------------------------------------------

10. Summary of Clinical Data

No clinical studies were considered necessary and performed.

11. Conclusion [21 CFR 807.92(b) (3)]

Subject Device is substantially equivalent to the currently marketed and predicate devices in terms of design features, fundamental scientific technology, indications for use, and safety and effectiveness.

Additionally, the safety of the subject device was validated through tests including IEC60601-1 and IEC 60601-1-2. The effectiveness of the device was validated through bench tests.

The results of these tests demonstrate that CW120N meets the acceptance criteria and is adequate for this intended use. The comparison of technological characteristics, non-clinical performance data, safety testing demonstrates that the device is as safe and effective as the predicate device and performs as well as the predicate device.

Regulation Number and Section

§ 892.2050 Medical image management and processing system.

(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).